ストックスクリーナーアプリを入手
1.96
1.01%
-0.02
アフターアワーズ：
1.95
-0.01
-0.51%
前日終値:
$1.98
開ける：
$1.98
24時間の取引高:
165.93K
Relative Volume:
0.66
時価総額：
$118.72M
収益：
-
当期純損益:
$-64.86M
株価収益率:
-1.75
EPS:
-1.12
ネットキャッシュフロー:
$-55.66M
1週間 パフォーマンス:
-1.75%
1か月 パフォーマンス:
+5.38%
6か月 パフォーマンス:
+68.97%
1年 パフォーマンス:
+5.95%
1日の値動き範囲:
$1.94
$2.0506
1週間の範囲:
$1.90
$2.14
52週間の値動き範囲:
$0.8551
$2.46
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
名前
Acumen Pharmaceuticals Inc
セクター
電話
617-344-4190
住所
1210-1220 WASHINGTON STREET, NEWTON
ABOS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.96 | 119.94M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2024-07-26 | 開始されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-20 | 再開されました | BofA Securities | Buy |
| 2023-05-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-07-15 | 開始されました | BTIG Research | Buy |
| 2022-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-07-26 | 開始されました | BofA Securities | Neutral |
| 2021-07-26 | 開始されました | Credit Suisse | Outperform |
| 2021-07-26 | 開始されました | Stifel | Buy |
| 2021-07-26 | 開始されました | UBS | Buy |
すべてを表示
Acumen Pharmaceuticals Inc (ABOS) 最新ニュース
Jindal Steel And Power Can the turnaround happenDividend Cut Warnings & Rapid Portfolio Investment - bollywoodhelpline.com
Arfin India Limited (539151) Quarterly Results Are OutEarnings Revision Updates & Free Gain Edge With Data - bollywoodhelpline.com
ABOS stock touches 52-week low at $1.52 amid market challenges - MSN
Acumen Pharmaceuticals, Inc. (ABOS) AI-Powered Stock Analysis - Meyka
Acumen Pharmaceuticals Earnings Notes - Trefis
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded at Wall Street Zen - MarketBeat
New Highs: Is Acumen Pharmaceuticals Inc. stock supported by innovation pipeline2025 Top Gainers & Precise Buy Zone Identification - Улправда
Is Acumen Pharmaceuticals Inc. stock a bargain at current levelsJuly 2025 Macro Moves & Technical Confirmation Alerts - DonanımHaber
Is Acumen Pharmaceuticals Inc. stock supported by innovation pipelineWeekly Risk Summary & Technical Analysis for Trade Confirmation - Улправда
Can Acumen Pharmaceuticals Inc. stock maintain operating margins2025 Sector Review & Risk Managed Investment Strategies - Улправда
Retail Surge: Is Acumen Pharmaceuticals Inc. stock supported by innovation pipeline2025 Pullback Review & Fast Entry Momentum Alerts - Улправда
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) versus Bolt Biotherapeutics (NASDAQ:BOLT) - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Downgraded to Sell Rating by Wall Street Zen - Defense World
Is Acumen Pharmaceuticals Inc. stock a dividend growth opportunityJuly 2025 Macro Moves & Real-Time Buy Zone Alerts - Newser
Can Acumen Pharmaceuticals Inc. stock hit analyst price targetsJuly 2025 WrapUp & AI Powered Buy/Sell Recommendations - Newser
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Acumen presents new research on Alzheimer’s treatment delivery By Investing.com - Investing.com Canada
Acumen Pharmaceuticals (ABOS) Stock Analysis Report | Financials & Insights - Benzinga
Acumen Pharmaceuticals Presents Results on Alzheimer’s Disease at Conference - Yahoo
Acumen and JCR Advance Next-Generation CNS Therapeutics with EBD™ Technology - citybiz
What analysts say about Acumen Pharmaceuticals Inc stockStock Liquidity Analysis & Invest Like A Pro - earlytimes.in
Acumen Pharmaceuticals highlights enhanced brain delivery technology for oligomer-selective antibodies - marketscreener.com
Acumen presents new research on Alzheimer’s treatment delivery - Investing.com
Acumen (NASDAQ: ABOS) reports CTAD results on 15 to 68-fold delivery and ALTITUDE-AD recruitment - Stock Titan
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Wall Street analysts’ outlook for Acumen Pharmaceuticals Inc (ABOS) - setenews.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.75 Average Target Price from Analysts - Defense World
Is Acumen Pharmaceuticals Inc a good long term investmentTrade Execution Strategies & Big Profit Small Investment - earlytimes.in
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2025-11-21 08:02:34 - newser.com
Will Acumen Pharmaceuticals Inc. stock go up soonTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com
Why Acumen Pharmaceuticals Inc. stock is favored by top institutionsWeekly Trade Summary & Free AI Powered Buy and Sell Recommendations - newser.com
Using data models to predict Acumen Pharmaceuticals Inc. stock movementQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com
How risky is Acumen Pharmaceuticals Inc. stock nowJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com
Is Acumen Pharmaceuticals Inc. stock dividend yield sustainableQuarterly Profit Summary & Verified Entry Point Signals - newser.com
Acumen Pharmaceuticals (ABOS) Price Target Decreased by 20.59% to 6.88 - MSN
Can Acumen Pharmaceuticals Inc. rally from current levelsTrade Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Acumen Pharmaceuticals Inc. stock recession proofJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
Reversal indicators forming on Acumen Pharmaceuticals Inc. stockJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NRXP), LifeMD (LFMD) and Hims & Hers Health (HIMS) - The Globe and Mail
Is Acumen Pharmaceuticals Inc. stock attractive for passive investorsQuarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com
B of A Securities Maintains Acumen Pharmaceuticals (ABOS) Buy Recommendation - Nasdaq
ABOS: B of A Securities Lowers Price Target But Maintains Buy Ra - GuruFocus
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - The Manila Times
SR Bancorp (NASDAQ: SRBK) announces $0.05 dividend payable Oct. 15 - Stock Titan
Acumen Pharmaceuticals Inc (ABOS) 財務データ
収益
当期純利益
現金流量
EPS
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):